Author

M. Lawler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:statistical model· 5 Research Focus:cell type annotation· 4 Research Focus:differential expression· 4 Assay:bulk RNA-seq· 3 Assay:imaging· 2 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

D. B. Longley· 3 shared P. D. Dunne· 3 shared A. Santamaria-Pang· 2 shared A. Sood· 2 shared B. Ahmaderaghi· 2 shared E. MCDonough· 2 shared F. Ginty· 2 shared M. B. Loughrey· 2 shared

Activity by Year

2017-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. B. Longley

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

MmCMS: Mouse models' Consensus Molecular Subtypes of colorectal cancer

R. Amirkhah, K. Gilroy, S. Malla, T. Lannagan, R. Byrne, N. C. Fisher, S. Corry, H. Naderi-Meshkin, B. Ahmaderaghi, R. Murray, M. Mills, A. Campbell, ACRCelerate consortium, A. Berenguer Llergo, R. Sanz-Pamplona, , P. Dunne

The paper develops three methods to classify mouse colorectal cancer models into human CMS subtypes, finding that pathway-level classifiers outperform gene-level ones for accurate subtype identification.

bioRxiv · Jun 17, 2022Cancer Biology

Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data

N. C. Fisher, R. Byrne, H. Leslie, C. Wood, A. Legrini, A. Cameron, B. Ahmaderaghi, S. Corry, S. Malla, R. Amirkhah, A. McCooey, E. Rogan, K. Redmond, S. Sakhnevych, E. Domingo, , P. D. Dunne

The paper shows that transcriptional signatures in tumour samples can be misinterpreted due to stromal influences, affecting alignment with preclinical data.

bioRxiv · Apr 15, 2022 · PreprintCancer Biology

An atlas of inter- and intra-tumor heterogeneityof apoptosis competency in colorectal cancertissue at single cell resolution

A. U. Lindner, M. Salvucci, E. MCDonough, S. Cho, X. Stachtea, E. P. O'Connell, A. D. Corwin, A. Santamaria-Pang, S. Carberry, M. Fichtner, S. Van Schaeybroeck, P. Laurent-Puig, J. P. Burke, D. McNamara, M. Lawler, , J. H. Prehn

The paper generates an atlas of apoptosis susceptibility heterogeneity in colorectal cancer using single-cell analysis and ODE modeling, identifying intrinsic cellular differences in apoptosis competency.

bioRxiv · Mar 19, 2021Cancer Biology

Stratification Of Chemotherapy-Treated Stage III Colorectal Cancer Patients Using Multiplexed Imaging And Single Cell Analysis Of T Cell Populations

X. Stachtea, M. B. Loughrey, M. Salvucci, A. Lindner, S. Cho, E. McDonough, A. Sood, J. Graf, A. Santamaria-Pang, A. Corwin, P. Laurent-Puig, S. Dasgupta, S. Van Schaeybroeck, M. Lawler, J. H. M. Prehn, , D. B. Longley

This study uses multiplexed imaging and single-cell analysis to classify immune cells in stage III colorectal cancer patients, finding that multi-marker Treg classification better predicts survival than single markers.

bioRxiv · Feb 24, 2021Cancer Biology

Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer

D. B. Longley, N. T. Crawford, K. J. Stott, T. Sessler, C. McCann, W. McDaid, C. Latimer, J. Fox, J. M. Munck, T. Smyth, A. Shah, V. Martins, M. Lawler, P. D. Dunne, E. M. Kerr, , V. M. Coyle

This study shows tolinapant, an IAP inhibitor, enhances chemotherapy-induced apoptosis in colorectal cancer by modulating FLIP and HDACs, suggesting its clinical use in poor prognosis MSS CRC with elevated cIAP1/2.

bioRxiv · Nov 20, 2020Cancer Biology

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer

P. D. Dunne, H. G. Coleman, P. Bankhead, M. Alderdice, R. T. Gray, S. McQuaid, V. Bingham, M. B. Loughrey, J. A. James, A. M. McCorry, A. Gilmore, C. Holohan, D. Klingbiel, S. Tejpar, P. G. Johnston, , M. Lawler

The paper identifies Bcl-xL as a prognostic biomarker and predictor of response to adjuvant chemotherapy in BRAF-mutant stage II/III colon cancer using gene expression and immunohistochemistry validation.

bioRxiv · Oct 23, 2017Cancer Biology